For advanced gBRCAm HER2-negative breast cancer, PARP inhibitors were approved based on the results of the OlympiAD (olaparib) and EMBRACA (talazoparib) clinical trials5,6,35,36. The gene discussed is ERBB2; the disease is breast carcinoma.